Lifeboat Foundation

The generation of a chemical system capable of replication and evolution is a key objective of synthetic biology. This could be achieved by in vitro reconstitution of a minimal self-sustaining central dogma consisting of DNA replication, transcription and translation. Here, we present an in vitro translation system, which enables self-encoded replication and expression of large DNA genomes under well-defined, cell-free conditions. In particular, we demonstrate self-replication of a multipartite genome of more than 116 kb encompassing the full set of Escherichia coli translation factors, all three ribosomal RNAs, an energy regeneration system, as well as RNA and DNA polymerases. Parallel to DNA replication, our system enables synthesis of at least 30 encoded translation factors, half of which are expressed in amounts equal to or greater than their respective input levels. Our optimized cell-free expression platform could provide a chassis for the generation of a partially self-replicating in vitro translation system.

Wall Street’s Biotech Investment Wizard — On this most recent ideaXme (http://radioideaxme.com/) episode, I was honored to be joined by my friend, and biotech / pharma / healthcare investment banker extraordinaire, Frederick Frank, to talk about his 50-year career history behind the industry’s mega-deals — #Ideaxme #Biopharma #Biotech #WallStreet #Mergers #Acquisitions #VentureCapital #Genentech #Roche #BristolMyersSquibb #PrivateEquity #Health #Wellness #Longevity #Regeneration #LifeExtension #Aging #IraPastor #Bioquark #Regenerage

Ira Pastor, ideaXme exponential health ambassador, interviews Fred Frank, Founder and Chair of Evolution Life Science Partners, an investment bank focused on the needs of life sciences and healthcare companies.

Continue reading “Biotech’s Wizard Of Wall Street : Fred Frank At The Forefront of Investment” »

Researchers suggest probiotic SLIC system could be adapted to generate and deliver a wide variety and combination of immunotherapeutics against different tumor types.

This is the first-ever 3D-printed human heart model using human cells #ValentinesDay

Still, the fact that many labs worldwide are capable of printing viruses is worrisome.

A few years ago, for instance, Canadian researchers alarmed the scientific community when they assembled synthetic horsepox in a lab — a virus closely related to smallpox, which killed hundreds of millions before researchers developed a vaccine.

The same technique, the researchers said at the time, could be be used to bring back smallpox, giving terrorists tools to set off a deadly pandemic.

Glioblastomas are relentless, hard-to-treat, and often lethal brain tumors. Yale scientists have enlisted a most unlikely ally in efforts to treat this form of cancer — elements of the Ebola virus.

“The irony is that one of the world’s deadliest viruses may be useful in treating one of the deadliest of brain cancers,” said Yale’s Anthony van den Pol, professor of neurosurgery, who describes the Yale efforts Feb. 12 in the Journal of Virology.

The approach takes advantage of a weakness in most cancer tumors and also of an Ebola defense against the immune system response to pathogens.

Plant pathogens elicit an immune response through effector proteins. In turn, plant genomes encode genes that determine species-specific recognition of these effectors by a process known collectively as effector-triggered immunity (ETI). By examining a range of strains of the pathogen Pseudomonas syringae that infect the model plant Arabidopsis thaliana, Laflamme et al. generated a P. syringae Type III Effector Compendium (PsyTEC) and in turn identified the genes responsible for ETI in Arabidopsis. This pan-genome analysis revealed that relatively few A. thaliana genes are responsible for recognizing the majority of P. syringae effectors. These results provide insight into why most pathogenic microbes only infect specific plant species.

Science, this issue p. 763

Effector-triggered immunity (ETI), induced by host immune receptors in response to microbial effectors, protects plants against virulent pathogens. However, a systematic study of ETI prevalence against species-wide pathogen diversity is lacking. We constructed the Pseudomonas syringae Type III Effector Compendium (PsyTEC) to reduce the pan-genome complexity of 5127 unique effector proteins, distributed among 70 families from 494 strains, to 529 representative alleles. We screened PsyTEC on the model plant Arabidopsis thaliana and identified 59 ETI-eliciting alleles (11.2%) from 19 families (27.1%), with orthologs distributed among 96.8% of P. syringae strains. We also identified two previously undescribed host immune receptors, including CAR1, which recognizes the conserved effectors AvrE and HopAA1, and found that 94.7% of strains harbor alleles predicted to be recognized by either CAR1 or ZAR1.

Hart’s demonstrations are entertainment for sure. But his message runs deeper: rhythm and vibration heal the brain. Dementia, he says, is the “loss of rhythm.” And he, along with notables who collaborated on the event — University of California at San Francisco neuroscientist Adam Gazzaley and opera singer Renée Fleming (who lent her soprano to the event’s musical track) — are all at work searching for pathways that can bypass obstacles to function and cognition. Hart has also worked with Dr. Connie Tomaino, who runs the Institute for Music and Neurologic Function, on music as a therapeutic tool for brain function.

Gazzaley is currently conducting clinical trials with healthy older adults to show how a regular regimen of digital rhythm can enhance attention and memory in people with cognitive impairment. Hart has been working with Gazzaley on what will be a downloadable app, their goal to develop a game that challenges one’s rhythmic ability, with the hope of building new neuropathways in the brain. “What we’re talking about here is a deeper and longer immersive experience which can actually harness the brain’s plasticity to change the way it functions,” says Gazzaley.

Taking up an instrument as a child, and playing through adulthood is one proven way to protect one’s brain. But learning later in life is helpful, too. Hart shares the story of his unlikely best friend, Walter Cronkite, who was 73 when he became a Deadhead, and also started playing the drums. In July of 2009, as Cronkite lay dying from complications of cerebrovascular disease, Hart handed him a hand drum. “He could no longer speak, but he could play,” Hart says, tears in his eyes. “He used to ask, ‘When we do we know we have found our groove?’ Well, he found it.”

An American biotech company says it created a coronavirus vaccine three hours after getting access to the virus’ genetic sequence in mid-January, and now scientists are racing to get the vaccine on the market in record time.

Continue Reading Below

Inovio Pharmaceuticals is based in Pennsylvania, but scientists in its laboratory in San Diego made the discovery.